NOVORAPID FLEXPEN 3 ML

NOVORAPID FLEXPEN 3 ML belongs to the class of anti-diabetic medications. It is a type of insulin analog which is prescribed in diabetic adults and children of age 2 years and above. This medicine is used to help improve blood sugar levels and glycemic control.

NOVORAPID FLEXPEN 3 ML is a fast-acting, man-made version of human insulin. It is produced by the process of biotechnology called recombinant DNA technology. In this technology, the DNA is purposefully altered to get the desired product by using a fungus called Saccharomyces cerevisiae. It is sold as a sterile, aqueous, clear, and colorless solution that contains insulin aspart along with other constituents like glycerin, phenol, metacresol, zinc, sodium chloride etc.

The dose of NOVORAPID FLEXPEN 3 ML is prescribed depending upon the need of the individual. Take NOVORAPID FLEXPEN 3 ML regularly and take it exactly as per your doctor’s advice. It is usually given in combination with intermediate-acting or long-acting insulin. It is administered subcutaneously (under the skin) 5-10 minutes before a meal, but make sure you eat a meal or snack within 10 minutes of the insulin injection to avoid low blood sugar. It can also be given immediately after the meal.

Yes, NOVORAPID FLEXPEN 3 ML causes weight gain when used alone or when taken along with other insulin therapies. This weight gain is a common phenomenon. The reason for weight gain is the decrease in excretion of glucose through urine. It may also occur due to the anabolic effects (promoting fat and protein formation) of insulin. Consult your doctor to know the exact reason and remedy for this.

If you are a type 1 diabetes patient, then yes, you have to take NOVORAPID FLEXPEN 3 ML for the rest of your life because your body is unable to produce sufficient insulin. Therefore, you would need NOVORAPID FLEXPEN 3 ML as an external source of insulin. However, if you are a type 2 diabetes patient, your doctor may ask you to stop NOVORAPID FLEXPEN 3 ML, in some cases, if you were able to manage your diabetes well and your blood sugar levels are controlled with exercise, diet, and oral medicines.

Yes, the use of NOVORAPID FLEXPEN 3 ML can cause hypoglycemia (low blood sugar level). Symptoms of hypoglycemia include nausea, headache, irritability, hunger, sweating, dizziness, fast heart rate, and feeling anxious or shaky. It happens more often if you miss or delay your food, drink alcohol, over-exercise, or take other antidiabetic medicines along with it. So, regular monitoring of the blood sugar level is important. Always carry some sugary candies, glucose biscuits, or fruit juice with you.

NOVORAPID FLEXPEN 3 ML is a fast-acting insulin which is given to improve blood sugar levels in patients with diabetes mellitus. Since this medicine starts working very quickly as compared to the regular insulin, it controls the immediate post-meal high blood sugar. Therefore, it can be injected subcutaneously 5-10 minutes before a meal. Moreover, if you miss taking it, you can also take it after your meal.

Yes, NOVORAPID FLEXPEN 3 ML is considered safe to use in pregnancy if prescribed by your doctor. Your dosage may need to be adjusted by your doctor and you may also require more frequent blood glucose monitoring. Consult your doctor if you become pregnant or are planning to become pregnant while using NOVORAPID FLEXPEN 3 ML.

NovoRapid FlexPen is a prefilled insulin pen containing insulin aspart, a rapid‑acting insulin analogue. It is used to control high blood glucose in people with diabetes mellitus, including type 1 and type 2 diabetes, who require insulin therapy. It provides mealtime (prandial) insulin coverage and is usually used in combination with a basal (long‑acting or intermediate‑acting) insulin or other antidiabetic medicines as prescribed.

Insulin aspart in NovoRapid has a slightly altered amino acid sequence compared with regular human insulin, which allows it to be absorbed more quickly from the subcutaneous tissue. As a result, NovoRapid has a faster onset of action and a shorter duration of effect. It typically starts working within about 10–20 minutes after injection, peaks within 1–3 hours, and lasts for about 3–5 hours, making it suitable for use around mealtimes.

NovoRapid FlexPen is generally injected immediately before a meal, as advised by your healthcare professional. In some cases, it may be injected shortly after starting a meal if recommended by your doctor. Because it acts quickly, injecting it too long before eating or skipping the meal can increase the risk of hypoglycaemia. Always follow the timing instructions given by your diabetes care team.

Any changes to your NovoRapid dose should be made under the guidance of a healthcare professional. Some patients are given individualized adjustment rules based on blood glucose readings, carbohydrate intake, and physical activity, but these should be clearly explained and agreed with your doctor or diabetes nurse. Do not increase, decrease, or stop NovoRapid on your own, as this can lead to serious hypo‑ or hyperglycaemia.

The most common side effect of NovoRapid is hypoglycaemia (low blood sugar), which can cause symptoms such as sweating, tremor, palpitations, hunger, headache, confusion, or irritability. Other possible side effects include injection‑site reactions (redness, swelling, pain, or itching), lipodystrophy (thickening or thinning of the fat tissue) at injection sites, and, rarely, allergic reactions. Severe hypoglycaemia can lead to loss of consciousness or seizures and requires urgent treatment.

Unopened NovoRapid FlexPens should be stored in a refrigerator at the temperature range specified in the product leaflet, and must not be frozen. Keep them away from the freezer compartment and from direct heat or light. After first use, the pen can usually be kept at room temperature for a limited period as stated in the package leaflet, provided it is kept below the maximum recommended temperature and protected from direct heat and sunlight. Always check the manufacturer’s instructions for exact storage conditions and discard the pen after the in‑use period has passed, even if insulin remains.

Yes, insulin aspart can be used in children and adolescents, including those with type 1 diabetes, from 1 year of age, when prescribed by a specialist experienced in paediatric diabetes. Dosing and monitoring in children require particular care, and caregivers should be thoroughly trained in injection technique, blood glucose monitoring, and recognition and management of hypoglycaemia.

If you forget to inject NovoRapid before a meal, follow the advice given by your healthcare team. In many cases, you may be instructed to inject shortly after you realize the omission and to monitor your blood glucose more frequently. Do not double your next dose to make up for a missed one. If you are unsure what to do, check your blood glucose and contact your doctor or diabetes nurse for individualized advice.

Alcohol can affect blood glucose levels and may increase the risk of both hypoglycaemia and hyperglycaemia in people using insulin, including NovoRapid. If you drink alcohol, do so in moderation, avoid drinking on an empty stomach, monitor your blood glucose more frequently, and be aware that symptoms of hypoglycaemia can be harder to recognize when drinking. Discuss alcohol use with your healthcare professional for personalized guidance.

Insulin is the preferred treatment for diabetes during pregnancy, and insulin aspart has been used in pregnant women under specialist supervision. Good blood glucose control before and during pregnancy is important to reduce risks for both mother and baby. Dose requirements often change during pregnancy and after delivery, so close monitoring and frequent contact with your diabetes team are essential. Insulin aspart can be used during breastfeeding; it does not pose a known risk to the breastfed infant when used as prescribed. However, your insulin needs may change after childbirth, and your doctor may need to adjust your regimen.

NovoRapid FlexPen is designed for use as a stand‑alone prefilled pen and should not be mixed with other insulins in the pen. Whether insulin aspart can be mixed with other insulins in a separate syringe depends on local product information and your prescriber’s instructions. In many treatment plans, rapid‑acting and basal insulins are given as separate injections. Always follow the specific guidance provided by your healthcare professional and the product leaflet.